
    
      This is a treatment development trial. Participants will be randomly assigned to BA in VR, BA
      in real-life, or a waitlist control group. The former two groups will follow a BA protocol
      developed for primary care settings over a four-week treatment period. This study is taking
      place over Zoom, due to COVID-19.
    
  